B-Raf is a tyrosine kinase-like kinase of the RAF family. Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Frequently mutated in thyroid cancers, skin melanomas and at lower frequency in a wide range of human cancers. An activating mutation, mimicking phosphorylation of the activation loop, is seen in 60% of malignant melanoma samples. Raf mutations are generally exclusive to Ras activating mutations. Activating mutations are also seen in ~10% of colorectal cancers, in lung cancers and gliomas, and at a lower rate in several other tumors. Inactivating mutations are also seen and may result in activation of c-Raf and Erk. Mutations in B-Raf, MEK1 and MEK2 also associated with cardiofaciocutaneous syndrome, displaying morphological, cardiac and mental defects. Approved Inhibitor: Nexavar/Sorafenib.
| Target |
BRAF |
| Reactivity |
Human |
| Host |
Mouse |
| Clonality |
Monoclonal |
| Tested Applications |
ELISA, WB, IHC |
| Recommended dilutions |
ELISA: 1/10000, WB: 1/500 - 1/2000, IHC: 1/200 - 1/1000. Optimal dilutions/concentrations should be determined by the end user. |
| Immunogen |
Purified recombinant fragment of BRAF expressed in E. Coli. |
| Purification |
Unpurified Ascites. |
| Isotype |
IgG1 |
| Conjugation |
Unconjugated |
| Storage |
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Molecular Weight |
84.4 kDa |
| Swiss Prot |
P15056
|
| GeneID |
673
|
| Gene Symbol |
BRAF |
| OMIM |
164757
|
| Enzyme Commission Number |
EC 2.7.1.37, EC 2.7.11.1 |
| HGNC |
1097 |
| Ensembl |
ENSG00000157764 |
| Buffer |
Ascitic fluid containing 0.03% sodium azide. |
| UNSPSC Code |
12352203 |
| Availability |
Shipped within 5-10 working days. |
| Note |
This product is for research use only. |